Elovanoids: Neuroprotection and Neurorestoration
NeuResto’s technology is based on the discovery of elovanoids that have potent neuroprotection (for ischemic stroke) and promote neurorestoration (for traumatic brain injury). Stroke and TBI are large neurologic unmet therapeutic needs. There are ~795,000 stroke cases of stroke in the US and an approximate 4 million concussion cases annually. Because of a lack of innovative new technologies, there is a need for new selective compounds with minimal toxicity.
Current therapy for stroke is thrombolysis, if the stroke is diagnosed within 3 hours and intracranial thrombectomy is done to restore flow if deemed to have salvageable brain tissue (penumbra). However, this helps at best half of patients achieve some measurable neurologic recovery (HERMES trial, NEJM 2017). Catheter-delivery of our technology to patients who undergo thrombectomy for ischemic stroke could help them achieve a better neurological functional outcome than thrombectomy alone because the elovanoids have been shown thru in vivo animal models to preserve the penumbra (brain tissue at risk but not dead) and prevent progression of the core infarct (dead brain tissue).
For TBI (e.g. military and sports concussions), the current therapy is to ‘rest.’ Elovanoids decrease neural excitotoxicity, inflammation and restore neural circuits. We envision on-field (e.g., sports and military) intranasal delivery of our potent neurorestoration therapy.
